top of page

Occam Recruits Sapna Srivastava to the Board of Nuvalent

Nuvalent, an F-Prime/Deerfield investment, develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events and drive more durable responses. The company went public in 2021 generating $166M.

In late 2021, Occam recruited Sapna Srivastava, PhD to the Board of Nuvalent. Sapna began her career as an equity analyst on Wall Street before taking on operating CFO roles at innovative biotechs like eGenesis, VelosBio, and Intellia.

bottom of page